A malaria vaccine has shown promising results in early stage clinical trials, a study suggests.
Researchers found the vaccine, which is being developed in the US, protected 12 out of 15 patients from the disease, when given in high doses.
The method is unusual because it involves injecting live but weakened malaria-causing parasites directly into patients to trigger immunity.
The research is published in the journal Science.
Lead author Dr Robert Seder, from the Vaccine Research Center at the National Institutes of Health, in Maryland, said: “We were excited and thrilled by the result, but it is important that we repeat it, extend it and do it in larger numbers.”
It has been known for several decades that exposure to mosquitoes treated with radiation can protect against malaria.
However, studies have shown that it takes more than 1,000 bites from the insects over time to build up a high level of immunity, making it an impractical method of widespread protection.
Instead, a US biotech company called Sanaria has taken lab-grown mosquitoes, irradiated them and then extracted the malaria-causing parasite (Plasmodium falciparum), all under the sterile conditions.
They are clearly very early stage trials in small numbers of volunteers, but without question we are extremely encouraged by the results”
Dr Ashley BirkettPath Malaria Vaccine Initiative
These living but weakened parasites are then counted and placed in vials, where they can then be injected directly into a patient’s bloodstream. This vaccine candidate is called PfSPZ.
To carry out the Phase-1 clinical trial, the researchers looked at a group of 57 volunteers, none of whom had had malaria before.
Of these, 40 received different doses of the vaccine, while 17 did not. They were then all exposed to the malaria-carrying mosquitoes.
The researchers found that for the participants not given any vaccine, and those given low doses, almost all became infected with malaria.
However for the small group given the highest dosage, only three of the 15 patients became infected after exposure to malaria.
Dr Robert Seder said: “Based on the history, we knew dose was important because you needed 1,000 mosquito bites to get protection – this validates that.
“It allows us in future studies to increase the dose and alter the schedule of the vaccine to further optimise it. The next critical questions will be whether the vaccine is durable over a long period of time and can the vaccine protect against other strains of malaria.”
The Latest on: Malaria vaccine
- Malaria Vaccines Market 2019 Global Share,Trend,Segmentation and Forecast to 2026on October 31, 2019 at 7:11 am
The malaria vaccines market is expected to reach USD 156.8 million by 2026. The market for malaria vaccines globally has been divided based on vaccine type, agent, channel of distribution and region.
- Researchers describe how malaria parasites prepare blueprint to attack humanson October 31, 2019 at 6:39 am
Dr. Stefan Kappe, senior author on the paper Dr. Stefan Kappe, the senior author on the paper published in Nature Communications and a malaria researcher in Seattle Children's Center for Global ...
- Transcriptomics and proteomics reveal two waves of translational repression during the maturation of malaria parasite sporozoiteson October 31, 2019 at 3:19 am
This disease, caused by Plasmodium parasites, affects over 200 million people annually and kills over 400,000 (WHO World Malaria Report 2018). While a protein-based subunit vaccine (RTS,S) has ...
- Research reveals how malaria parasite plans ahead, preparing blueprint to strike in humanson October 31, 2019 at 3:04 am
"It's cool biology that offers new insight into how we might begin to stop the parasite from infecting the liver." Researchers get a closer look at the parasite inside the mosquito An effective ...
- New vaccine shows promise against tuberculosison October 31, 2019 at 2:01 am
The vaccine, manufactured by drugmaker GlaxoSmithKline, is called M72/AS01E, and it was shown to be effective at preventing progression to pulmonary TB in more than half of the participants in the ...
- Malaria Parasite, Plasmodium Transfers From Gorillas To Humans: Studyon October 30, 2019 at 1:00 pm
falciparum parasite to infect humans. As such, RH5 is a promising malaria vaccine target – if this interaction can be disrupted, the parasite would no longer be able to invade human red blood cells ...
- Botched jabs: Busia County to compensate families of children paralyzed by toxic vaccineon October 30, 2019 at 2:36 am
A father holds his daughter who was partly paralysed after receiving a toxic malaria injection at the Akichelesit dispensary in Busia County in 2015 (Chrispen Sechere) The Busia County Government has ...
- Editing mosquito's gene wards off malaria and halts reproductionon October 29, 2019 at 5:04 am
"When a mosquito does not have functional ovaries, the parasite that causes malaria will not survive well in the mosquito," Fikrig said. "If we understand how malaria interacts with a mosquito, we can ...
- 43,000 Nigerian children lack access to polio vaccines –Gates Foundationon October 26, 2019 at 1:38 am
The Gates Foundation not too long ago announced that it was investing in a malaria vaccine. How far has that gone given the fact that malaria is still the number one cause of death in Nigeria? Malaria ...
- Indians will be infected with malaria, cholera and flu as part of new vaccination trialson October 22, 2019 at 10:11 pm
New Delhi: Healthy human beings are likely to be infected with malaria, cholera, influenza, typhoid and other diseases as part of new trials meant to test the efficacy of preventive vaccines and ...
via Google News and Bing News